Loren McCoy, MD
Internal Medicine · Muscle Shoals, ALNPI 1447312822
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,873 of the $48,053 with a category attached, or 74.7%. AbbVie accounts for 69.3% of it on its own, with 47 other manufacturers making up the rest. Reporting peaked in 2021 at $13,162 and has fallen 51.4% since, to $6,402 in 2025. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 869 payments — averaging $55.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Phathom Pharmaceuticals, Inc.$4K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Pfizer$843
- plus $5K from 42 others
Across 9 payments — averaging $4045.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$19K
- Eli Lilly$13K
- Chiesi USA, Inc.$5K
What the payments were for
- Speaking & faculty fees$35,87375%
- Travel & lodging$770%
- Food & beverage$12,08125%
- Education$230%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,053 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 320 | $383,012 |
| MounjaroTirzepatide | 312 | $346,970 |
| EliquisApixaban | 280 | $243,310 |
| JardianceEmpagliflozin | 189 | $182,163 |
| TrulicityDulaglutide | 116 | $126,296 |
| FarxigaDapagliflozin Propanediol | 154 | $119,409 |
| XareltoRivaroxaban | 130 | $113,895 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 97 | $78,026 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 78 | $66,285 |
| LinzessLinaclotide | 63 | $53,667 |
| EntrestoSacubitril/Valsartan | 42 | $49,107 |
| Tresiba Flextouch U-200Insulin Degludec | 54 | $44,669 |
| VascepaIcosapent Ethyl | 93 | $39,973 |
| JanuviaSitagliptin Phosphate | 26 | $33,974 |
| GlyxambiEmpagliflozin/Linagliptin | 39 | $29,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,277 | $473,267428 claims |
| Novo NordiskOzempic | $2,373 | $383,012320 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Jentadueto, Tradjenta | $367 | $317,806348 claims |
| PfizerEliquis, Premarin | $843 | $255,212314 claims |
| AstraZenecaFarxiga | $1,117 | $119,409154 claims |
| Johnson & JohnsonXarelto | $457 | $113,895130 claims |
| AbbVieLinzess, Vraylar, Ubrelvy | $33,300 | $99,64994 claims |
| GSKTrelegy Ellipta | $359 | $78,02697 claims |
| NovartisEntresto | $314 | $49,10742 claims |
| MerckJanuvia, Janumet Xr | $104 | $48,69049 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $69 | $26,75645 claims |
| Astellas Pharma US IncMyrbetriq | $174 | $21,15637 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Muscle Shoals
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
- Thomas HuddleBirmingham$76K
- Rahel AzizMobile$67K
- Justin HoveyDothan$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.